Navigation Links
NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204

IRVINE, Calif., March 24 /PRNewswire-FirstCall/ -- NuRx Pharmaceuticals, Inc. (OTC Bulletin Board: NURX) today announced it has dosed the first patient in a Phase I clinical trial of the first-in-class rexinoid receptor (RXR) agonist NRX4204.

The single-center study, which NuRx expects to complete in the fourth quarter of this year, is designed to evaluate the safety and tolerability of the compound. NRX4204 is the company's first drug candidate in clinical trials.

"Our preclinical data show that NRX4204 is a highly potent and specific, orally bio-available RXR agonist that is effective in models of non-small cell lung cancer and breast cancer," said Harin Padma-Nathan, M.D., NuRx's president and CEO. "We intend to pursue the development of this compound as a treatment for both indications. There are no rexinoid treatments currently approved for these indications."

NuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation retinoid and rexinoid compounds for application in oncology (treatment, prevention and adjunctive supportive therapy) and other highly prevalent diseases. The company's lead compounds are NRX4204, a highly specific, first-in-class rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer and a RAR agonist for the treatment of acute leukemia. Based in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this news release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the fact that the Company is engaged in early stage research and does not expect to obtain any revenues for several years and other risks as detailed from time to time in the Company's registration statement and reports and filings with the Securities and Exchange Commission. All forward-looking statements, if any, in this news release represent the Company's judgment as of the date of this news release. The Company disclaims, however, any intent or obligation to update forward-looking statements.


David Schull

(212) 845-4271


Parag Dave

(917) 322-2585

SOURCE NuRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with ... digital component is distributed nationally, through a vast social media strategy and across ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... failing. Secura Consultants has prided itself for not only fulfilling the needs of ... protection solutions at an affordable price and providing top-tier customer service. However, there's ...
Breaking Medicine News(10 mins):